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Abstract It has been confirmed recently that the volun-
teer effect in lung cancer screening is characterized by
higher lung cancer mortality risk in self-selected screening
participants. The Mayo Lung Project, the most influential
trial of screening for lung cancer ever completed, was
conducted in nonvolunteer Mayo Clinic outpatients, with a
peculiar study design that rendered the randomization
vulnerable to the volunteer effect. Of all nonvolunteers
randomized in the Mayo Lung Project, only those allocated
in the screened group were asked consent to participate in
the trial. The final Mayo Lung Project report stated that 655
randomized nonvolunteers refused screening and were
excluded from the study, thus documenting violation of the
rule that no selection should occur after randomization.
The long-term follow-up of the Mayo Lung Project showed
an enigmatic result which has never been explained: the
lung cancer mortality was 13% higher in the screening
intervention group than in the control group [4.4 (95% CI
3.9–4.9) vs. 3.9 (95% CI 3.5–4.4) per 1,000 person-years;
P = 0.09]. Such overrepresented mortality is consistent
with the volunteer effect and supports the concept that the
Mayo Lung Project randomization was compromised by
the post-randomization self-selection of participant
nonvolunteers.
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Dear Editor,
The volunteer effect has been studied extensively in
screening trials for cancer of the breast, colon-rectum and
prostate [1–3], but it has been scarcely investigated in the
context of screening for lung cancer (LC). The Johns
Hopkins Lung Project first documented that the LC mor-
tality of volunteers screened by chest X-rays (CXR) was
significantly higher than expected on the basis of two large
population studies, namely the Veterans Study [observed/
expected LC mortality ratio 1.72; 95% confidence interval
(CI) 1.28–2.18] and the American Cancer Society Study
(observed/expected LC mortality ratio 1.46; 95% CI
1.09–1.83) [4]. Recently, in a population-based study of
smokers offered CXR screening we confirmed that the
volunteer effect is characterized by significantly higher LC
mortality risk in self-selected participants compared to
nonparticipants (risk ratio 1.40; 95% CI, 1.03–1.91) [5].
The volunteer effect may bias the results of comparative
LC screening studies of nonvolunteers, if the latter are not
randomized adequately. The Mayo Lung Project (MLP),
the most influential trial of CXR screening for LC [6, 7],
was conducted in nonvolunteer Mayo Clinic outpatients
with a peculiar design that rendered the randomization
vulnerable.
Indeed the details of the MLP randomization, described
on page 1375 in the preliminary report [8], specify that:
‘‘the random assignment to the close-surveillance or the
control group is made at the interview. Up to this point,
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the Mayo Lung Project has not been mentioned, and, if the
assignment is to the control group, nothing is said of it and
the interview ends. If the assignment is to the close-sur-
veillance group, however, the interviewer explains that
program to the candidate and obtains his informed consent
and agreement to take part in it’’.
Accordingly, the MLP candidates were first randomized
and subsequently only the nonvolunteers allocated in the
screened group were asked consent to participate in
the trial; because of that study design we hypothesize that
the MLP randomization was likely compromised by the
volunteer bias.
The final MLP report stated that 655 randomized non-
volunteers refused screening and were excluded from the
study [9], thus documenting violation of the rule that no
selection should occur after randomization. After such
selection and exclusion of candidates, an important meth-
odological weakness, there is no guarantee that the
screening and control groups at baseline were well matched
for all known and unknown LC risks [10]. Notably, the
extended follow-up of the MLP showed two puzzling
results: (1) in 16 years after the end of screening
(1983–1999) the total number of newly diagnosed LCs was
11% greater in the screened group than in controls (379 vs.
340) [11], an excess certainly not attributable to screening
overdiagnosis; (2) the LC mortality was 13% higher in the
screening intervention group than in the control group [4.4
(95% CI 3.9–4.9) vs. 3.9 (95% CI 3.5–4.4) per 1,000
person-years; P = 0.09] [12]. These enigmatic results are
consistent with the volunteer effect in the LC screening
group; moreover, they support the concept that the docu-
mented post-randomization selection of nonvolunteers
compromised the MLP randomization.
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